ATLANTA, GA, Nov. 17, 2023 (GLOBE NEWSWIRE) -- Regional Health Properties, Inc. (the “Company,” “Regional Health,” “we”, “us” or “our”) (NYSE American: RHE) (NYSE American: RHE-PA), a self-managed healthcare real estate investment company that invests primarily in real estate purposed for senior living and long-term care, today announced its financial results for the third quarter ended September 30, 2023.
THIRD QUARTER 2023 FINANCIAL HIGHLIGHTS
THIRD QUARTER BUSINESS HIGHLIGHTS
MANAGEMENT COMMENTS
Brent Morrison, Regional Health’s President and Chief Executive Officer, commented, “Our operating partners continue to make progress mitigating lower than average occupancy and tight labor markets. As a result, our EBITDAR 3 coverage remains strong at 1.5x. We remain hopeful this momentum will continue into the fourth quarter as well as 2024”
Mr. Morrison continued, “With the transformative transaction behind us, we continue to look for opportunities to further simplify our capital structure and further reduce corporate expenses. As our stock price continues to trade well below net asset value, management remains committed to improve transparency for investors.”
FINANCIAL RESULTS FOR QUARTER ENDED SEPTEMBER 30, 2023
For the third quarter 2023, the Company reported total revenue of $4.1 million, a net loss of $1.0 million, EBITDA2 of $0.3 million and Adjusted EBITDA of $0.7 million.
BALANCE SHEET AND LIQUIDITY
As of September 30, 2023, the Company had $51.4 million of outstanding indebtedness with a weighted-average annual interest rate of 5.1% and a weighted-average maturity of approximately 19 years.
For the nine months ended September 30, 2023, net cash provided by operating activities was $3.4 million as compared to net cash used in operating activities of $2.2 million for the nine months ended September 30, 2022.
About Regional Health Properties
Regional Health Properties, Inc., a Georgia corporation, is a self-managed healthcare real estate investment company that invests primarily in real estate purposed for senior living and long-term care. For more information, visit www.regionalhealthproperties.com.
Important Cautions Regarding Forward-Looking Statements
This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as “expects,” “intends,” “believes,” “anticipates,” “plans,” “likely,” “will,” “seeks,” “estimates” and variations of such words and similar expressions are intended to identify such forward-looking statements. This press release includes forward-looking statements that reflect the Company’s current views with respect to, among other things, its business, operations, financial performance, revenue, capital structure, the impact of the exchange offer and economic developments.
Forward-looking statements, by their nature, involve estimates, projections, goals, forecasts and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those projected or contemplated by our forward-looking statements due to various factors, including, among others: our dependence on the operating success of our operators; the amount of, and our ability to service, our indebtedness; covenants in our debt agreements that may restrict our ability to make investments, incur additional indebtedness and refinance indebtedness on favorable terms; the availability and cost of capital; our ability to raise capital through equity and debt financings or through the sale of assets; increases in market interest rates and inflation; our ability to meet the continued listing requirements of the NYSE American LLC and to maintain the listing of our securities thereon; the effect of increasing healthcare regulation and enforcement on our operators and the dependence of our operators on reimbursement from governmental and other third-party payors; the relatively illiquid nature of real estate investments; the impact of litigation and rising insurance costs on the business of our operators; the impact on us of litigation relating to our prior operation of our healthcare properties; the effect of our operators declaring bankruptcy, becoming insolvent or failing to pay rent as due; the ability of any of our operators in bankruptcy to reject unexpired lease obligations and to impede our ability to collect unpaid rent or interest during the pendency of a bankruptcy proceeding and retain security deposits for the debtor’s obligations; our ability to find replacement operators and the impact of unforeseen costs in acquiring new properties; epidemics or pandemics, including the COVID-19 pandemic, and the related impact on our tenants, operators and healthcare facilities; and other factors discussed from time to time in our news releases, public statements and documents filed by us with the Securities and Exchange Commission from time to time, including our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. These forward-looking statements and such risks, uncertainties and other factors speak only as of the date of this press release, and we expressly disclaim any obligation or undertaking to update or revise any forward-looking statement contained herein, to reflect any change in our expectations with regard thereto or any other change in events, conditions or circumstances on which any such statement is based, except to the extent otherwise required by applicable law.
| Company Contact |
| Brent Morrison, CFA |
| Chief Executive Officer & President |
| Regional Health Properties, Inc. |
| Tel (678) 368-4402 |
| This email address is being protected from spambots. You need JavaScript enabled to view it. |
REGIONAL HEALTH PROPERTIES, INC.
STATEMENT OF OPERATIONS
(Amounts in thousands, except per share data)
(Unaudited)
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| 2023 | 2022 | 2023 | 2022 | |||||||||||||
| Revenues: | ||||||||||||||||
| Patient care revenues | $ | 2,136 | $ | 7,769 | $ | 6,577 | $ | 14,650 | ||||||||
| Rental revenues | 1,739 | 3,000 | 5,170 | 10,326 | ||||||||||||
| Management fees | 263 | 255 | 788 | 774 | ||||||||||||
| Other revenues | — | 6 | 107 | 20 | ||||||||||||
| Total revenues | 4,138 | 11,030 | 12,642 | 25,770 | ||||||||||||
| Expenses: | ||||||||||||||||
| Patient care expense | 2,313 | 7,476 | 7,010 | 14,040 | ||||||||||||
| Facility rent expense | 149 | 1,451 | 446 | 4,725 | ||||||||||||
| Cost of management fees | 156 | 140 | 442 | 459 | ||||||||||||
| Depreciation and amortization | 526 | 600 | 1,738 | 1,819 | ||||||||||||
| General and administrative expense | 972 | 1,378 | 3,190 | 3,432 | ||||||||||||
| Doubtful accounts expense | 229 | 1,515 | 269 | 3,742 | ||||||||||||
| Other operating expenses | 197 | 441 | 511 | 1,409 | ||||||||||||
| Total expenses | 4,542 | 13,001 | 13,606 | 29,626 | ||||||||||||
| Income/(loss) from operations | (404 | ) | (1,971 | ) | (964 | ) | (3,856 | ) | ||||||||
| Other expense: | ||||||||||||||||
| Interest expense, net | 708 | 564 | 2,066 | 1,855 | ||||||||||||
| Other expense, net | (139 | ) | (2,164 | ) | 620 | (1,088 | ) | |||||||||
| Total other (income) expense, net | 569 | (1,600 | ) | 2,686 | 767 | |||||||||||
| Net loss | $ | (973 | ) | $ | (371 | ) | $ | (3,650 | ) | $ | (4,623 | ) | ||||
| Preferred stock dividends - undeclared | — | (2,249 | ) | — | (6,748 | ) | ||||||||||
| Preferred stock dividends - gain on extinguishment | — | — | 43,395 | — | ||||||||||||
| Net profit (loss) attributable to Regional Health Properties, Inc. common stockholders | $ | (973 | ) | $ | (2,620 | ) | $ | 39,745 | $ | (11,371 | ) | |||||
| Net profit (loss) per share of common stock attributable to Regional Health Properties, Inc. | ||||||||||||||||
| Basic: | $ | (0.52 | ) | $ | (1.48 | ) | $ | 21.18 | $ | (6.40 | ) | |||||
| Diluted: | $ | (0.52 | ) | $ | (1.48 | ) | $ | 21.18 | $ | (6.40 | ) | |||||
| Weighted average shares of common stock outstanding: | ||||||||||||||||
| Basic: | 1,883,028 | 1,768,720 | 1,876,138 | 1,775,637 | ||||||||||||
| Diluted: | 1,883,028 | 1,768,720 | 1,876,138 | 1,775,637 | ||||||||||||
REGIONAL HEALTH PROPERTIES, INC.
BALANCE SHEET
(Amounts in thousands)
(Unaudited)
| September 30, 2023 | December 31, 2022 | |||||||
| ASSETS | ||||||||
| Property and equipment, net | $ | 45,806 | $ | 46,611 | ||||
| Cash | 1,427 | 843 | ||||||
| Restricted cash | 3,208 | 3,066 | ||||||
| Accounts receivable, net of allowances of $1,579 and $1,298 | 2,035 | 6,289 | ||||||
| Prepaid expenses and other | 903 | 746 | ||||||
| Notes receivable | 1,060 | 1,099 | ||||||
| Intangible assets - bed licenses | 2,471 | 2,471 | ||||||
| Intangible assets - lease rights, net | 92 | 110 | ||||||
| Right-of-use operating lease assets | 2,588 | 2,848 | ||||||
| Goodwill | 1,585 | 1,585 | ||||||
| Lease deposits and other deposits | 4 | — | ||||||
| Straight-line rent receivable | 2,830 | 2,912 | ||||||
| Total assets | $ | 64,009 | $ | 68,580 | ||||
| LIABILITIES AND EQUITY | ||||||||
| Senior debt, net | $ | 44,208 | $ | 45,163 | ||||
| Bonds, net | 5,989 | 6,120 | ||||||
| Other debt, net | 1,181 | 895 | ||||||
| Accounts payable | 2,783 | 3,293 | ||||||
| Accrued expenses | 4,806 | 5,036 | ||||||
| Operating lease obligation | 2,948 | 3,226 | ||||||
| Other liabilities | 1,707 | 1,131 | ||||||
| Total liabilities | 63,622 | 64,864 | ||||||
| Stockholders’ equity: | ||||||||
| Common stock and additional paid-in capital | 63,023 | 62,702 | ||||||
| Preferred stock, Series A | 426 | 62,423 | ||||||
| Preferred stock, Series B | 18,602 | — | ||||||
| Accumulated deficit | (81,664 | ) | (121,409 | ) | ||||
| Total stockholders’ equity | 387 | 3,716 | ||||||
| Total liabilities and stockholders’ equity | $ | 64,009 | $ | 68,580 | ||||
REGIONAL HEALTH PROPERTIES, INC.
DEBT SUMMARY
(Amounts in thousands)
(Unaudited)
| September 30, 2023 | ||||||||||||||||||||||||||||
| Maturity | Interest Rate | Principal | % of Principal | Deferred financing costs | Unamortized discount on bonds | Net Carrying Value | ||||||||||||||||||||||
| Total Fixed Rate Debt | 2042 | 4.28 | % | 44,569 | 85.0 | % | (767 | ) | (115 | ) | 43,687 | |||||||||||||||||
| Total Floating Rate Debt | 2036 | 9.92 | % | 7,895 | 15.0 | % | (204 | ) | - | 7,691 | ||||||||||||||||||
| Total | $ | 52,464 | 100.0 | % | $ | (971 | ) | $ | (115 | ) | $ | 51,378 | ||||||||||||||||
Calculation of Non-GAAP Financial Measures
This press release presents information about EBITDA adjusted EBITDA and EBITDAR, which are non-GAAP financial measures provided as a supplement to the results provided in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The Company believes that these non-GAAP financial measures provide meaningful supplemental information regarding its performance by excluding certain items that may not be indicative of its recurring core business operating results. The Company believes that both management and investors benefit from referring to these non-GAAP financial measures in assessing its performance and when planning and forecasting future periods. These non-GAAP financial measures also facilitate management’s internal comparisons to the Company’s historical performance. The Company believes these non-GAAP financial measures are useful to investors in allowing for greater transparency with respect to supplemental information used by management in its financial and operational decision making.
These non-GAAP financial measures are presented for supplemental informational purposes only. These non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation from, or as a substitute for, GAAP financial measures. These non-GAAP financial measures may differ from the non-GAAP financial measures used by other companies. A reconciliation of the non-GAAP financial measures to the most directly comparable GAAP financial measure is provided below for each of the fiscal periods indicated.
A reconciliation of EBITDA and adjusted EBITDA is as follows:
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| 2023 | 2022 | 2023 | 2022 | |||||||||||||
| Net income (loss) | (973 | ) | (371 | ) | (3,650 | ) | (4,623 | ) | ||||||||
| Depreciation and amortization | 526 | 600 | 1,738 | 1,819 | ||||||||||||
| Interest expense, net | 708 | 564 | 2,066 | 1,855 | ||||||||||||
| Amortization of employee stock compensation | 86 | 58 | 321 | 173 | ||||||||||||
| EBITDA | 347 | 851 | 475 | (776 | ) | |||||||||||
| Bad debt - straight line write off | 229 | 1,383 | - | 3,760 | ||||||||||||
| Bad debt - Increase in provision | - | 150 | 278 | 150 | ||||||||||||
| Discontinuted operations | (200 | ) | (2,321 | ) | (231 | ) | (2,321 | ) | ||||||||
| Gain on Foster leases modification | - | (140 | ) | - | (140 | ) | ||||||||||
| Expenses related to preferred stock recapitalization | 95 | 158 | 768 | 1,232 | ||||||||||||
| Other one-time costs | 6 | 63 | 270 | 92 | ||||||||||||
| Project costs | 70 | - | 237 | - | ||||||||||||
| Tail insurance on legacy facilities | 127 | - | 512 | - | ||||||||||||
| One-time income adjustment - quality incentive program | - | - | - | - | ||||||||||||
| Adjusted EBITDA from operations | $ | 674 | $ | 144 | $ | 2,309 | $ | 1,997 | ||||||||
1 Adjusted EBITDA is a non-GAAP financial measure. See “Calculation of Non-GAAP Financial Measures” for important additional information.
2 EBITDA is a non-GAAP financial measure. See “Calculation of Non-GAAP Financial Measures” for important additional information.
3 EBITDAR is a non-GAAP financial measure.
| Last Trade: | US$1.55 |
| Daily Change: | 0.15 10.86 |
| Daily Volume: | 118,673 |
| Market Cap: | US$2.950M |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
